FDA rejects J&J’s subcutaneous Rybrevant over manufacturing issuesnews2024-12-17T12:05:04+00:00December 17th, 2024|Endpoints News|
AstraZeneca denied full FDA approval of Andexxa after adcommnews2024-12-16T20:54:51+00:00December 16th, 2024|Endpoints News|
Viridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye diseasenews2024-12-16T20:14:30+00:00December 16th, 2024|Endpoints News|
What a Trump FTC means for biotech and pharma dealmakingnews2024-12-16T18:48:14+00:00December 16th, 2024|Endpoints News|
HRSA pushes back against another 340B rebate model, this time from Sanofinews2024-12-16T18:08:37+00:00December 16th, 2024|Endpoints News|
Neurocrine gets FDA approval in rare adrenal gland conditionnews2024-12-16T17:07:26+00:00December 16th, 2024|Endpoints News|
Checkpoint wins FDA approval of checkpoint inhibitor in advanced skin cancer, seeks partner for launchnews2024-12-16T16:23:12+00:00December 16th, 2024|Endpoints News|
Organon’s steroid-free cream Vtama wins approval in atopic dermatitisnews2024-12-13T20:53:06+00:00December 13th, 2024|Endpoints News|
McKinsey fined $650M for deceiving US on opioid consultingnews2024-12-13T20:40:09+00:00December 13th, 2024|Endpoints News|
FDA stands by mifepristone safety label in federal court challengenews2024-12-13T20:03:13+00:00December 13th, 2024|Endpoints News|
